Law Sau Fai Institute For Advancing Translational Medicine In Bone&Joint Diseases, Hong Kong Baptist University Aiping Lyu Chair Professor (Dr. Wong Y. H. Chair Professor) is a world-leading scientist in the field of aptamer translational medicine and drug discovery. He is not only committed to basic research on precision medicine classification and treatment strategies for rheumatism, but is also committed to translational research in cooperation with pharmaceutical companies to develop new therapeutic drugs. He is the creator of the first aptamer drug research and development platform in China’s Guangdong-Hong Kong-Macao Greater Bay Area (https://www.hkaptamer.com). This platform has attracted many aptamer pharmaceutical industries to establish the "Aptamer Drug Valley" in the Hong Kong Science Park. He developed the world's first nucleic acid aptamer targeting osteoblasts. The therapeutic aptamer drug targeting sclerostin loop3 developed by Professor Lyu in collaboration with Aptacure has been granted Orphan Drug Designation (DRU-2019-6966) by the US FDA for the treatment of osteogenesis imperfecta. He also developed the first aptamer-paclitaxel conjugate, demonstrating a precision medicine-based personalized paclitaxel for targeting specific cancer types, which is currently being developed into an anti-cancer drug by a pharmaceutical company.

Chair Professor Aiping Lyu’s The Academy of Europe member page: https://www.ae-info.org/ae/Member/Lyu_Aiping